Consent given pursuant to Sections 14 and 14A to the supply of the therapeutic goods specified by Nestle Australia

Overview

The Therapeutic Goods Act 1989, enacted by the Parliament of Australia, was introduced to regulate the supply, advertising, and importation of therapeutic goods in Australia. This comprehensive legislation aims to protect public health by ensuring that therapeutic goods available in the market meet safety, quality, and efficacy standards. A notable instance of its application occurred on 1 December 2015, when the Secretary of the Department of Health granted a consent under sections 14 and 14A of the Act to Nestle Australia Ltd, allowing the supply of certain products that did not fully comply with the labelling requirements of Therapeutic Goods Order No. 69. This consent, effective until 1 December 2016, was subject to conditions ensuring that the products were enclosed in primary packs meeting the specified labelling requirements, thereby balancing regulatory compliance with practical market conditions. The Act’s policy objective is to safeguard public health by regulating therapeutic goods, and the consent granted in this instance reflects the TGA's approach of ensuring compliance while considering the specifics of product distribution and consumer safety. By permitting the supply of non-compliant products under certain conditions, the Act demonstrates its flexibility in addressing unique situations while upholding its overarching goal of protecting the health of the Australian public.

Scope and Application

The Therapeutic Goods Act 1989 applies to a broad range of therapeutic goods, including medicines, medical devices, blood, and tissues, within the Commonwealth of Australia. This Act encompasses both natural and synthetic substances that are intended for use in the diagnosis, treatment, mitigation, or prevention of disease, abnormality, or injury in humans or animals. The Act applies to all entities involved in the manufacturing, importing, supplying, and advertising of therapeutic goods, ensuring that they comply with specified standards and regulations. The Act's jurisdictional reach is national, with enforcement by the Therapeutic Goods Administration (TGA) under the Department of Health, ensuring consistency across states and territories. Notably, certain goods may be exempt from certain provisions under the Act, depending on their classification and use, although specific exclusions are detailed in the various Therapeutic Goods Orders (TGOs) that provide further regulatory detail. The application of the Act can be extended or restricted through subordinate instruments, such as TGOs, which provide specific rules and standards that therapeutic goods must meet.

Key Provisions

Under sections 14 and 14A of the Therapeutic Goods Act 1989, the Secretary of the Department of Health has the authority to consent to the supply of therapeutic goods that do not fully comply with certain regulatory requirements. In this instance, Nestle Australia Ltd applied for such consent concerning the supply of Soothers Liquid Centres – Mixed Berry and Soothers Liquid Centres – Lemon & Lime. The specific non-compliance related to the labelling of individual lozenges, where the product name, active ingredients, and their quantities were not fully displayed on each unsealed wrapper, contrary to subclause 3(12)(a) of Therapeutic Goods Order No. 69 (TGO 69). This consent was granted effective from the date of the decision letter until 1 December 2016, subject to certain conditions. The Act imposes several obligations on the parties involved in the supply of therapeutic goods. Firstly, the primary condition of this consent is that the unsealed, individually wrapped lozenges must be enclosed in a primary pack that adheres to the requirements of subclauses 3(2) and 3(3) of TGO 69. This means the primary pack must still meet certain labelling standards to ensure consumers have access to essential information about the product. Additionally, the consent requires compliance with all other relevant provisions of the Therapeutic Goods Act 1989 and any applicable regulations and orders. The consent is also subject to review, and the Therapeutic Goods Administration (TGA) retains the right to revoke it if the conditions are not met. In terms of legal consequences, the Therapeutic Goods Act 1989 outlines various offences and penalties for breaches of its provisions. If a party fails to comply with the conditions of the consent granted under sections 14 and 14A, they may face civil or criminal penalties. For instance, supplying therapeutic goods that do not comply with the Act’s requirements can result in substantial fines. For companies, the maximum penalty can be up to $1.1 million for each individual contravention, while for individuals, the penalty can be up to $220,000 for each individual contravention. Additionally, supplying non-compliant goods can lead to criminal charges, with potential imprisonment for individuals found guilty. The seriousness of the penalties underscores the importance of adhering to the regulatory requirements governing the supply of therapeutic goods in Australia.